Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2003
03/19/2003EP0670904B1 Vector for the expression of therapy-relevant genes
03/19/2003EP0595935B1 Papillomavirus Vaccine
03/19/2003EP0463101B2 Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
03/19/2003CN1404484A Pluraflavins and derivatives thereof, process for their preparation and use thereof
03/19/2003CN1404481A Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes
03/19/2003CN1404480A Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes
03/19/2003CN1404479A Novel 1,3-dihydro-2H-indol-2-one derivatives their preparing method and the pharmceutical composition containing the same
03/19/2003CN1404476A Glycosidase inhibitors and preparation thereof
03/19/2003CN1404468A Novel use of phenylheteroalkylamine derivatives
03/19/2003CN1404402A Radioactive therapeutic Liposomes
03/19/2003CN1403484A Prepn and application of transmembrane staphylococcus aureus toxin A fusion protein
03/19/2003CN1403469A Antineoplastic compound and its prepn and medicinal use
03/19/2003CN1403439A Phytosphingosine derivate with antitumor activity
03/19/2003CN1403150A Medical health oral liquid and its prepn
03/19/2003CN1403147A Medicines composition for raising body's immunity and its prepn
03/19/2003CN1403114A Production process of cancer-eliminating pearl powder
03/19/2003CN1103232C Anticancer compound agent
03/19/2003CN1103227C Application of total saponin of Aralia elata (miq.) seem in preparation of antitumor medicine
03/18/2003WO2002024712A1 Triazolo-epothilones
03/18/2003US6535943 Information processing device enabling floating interrupt to be pending and a method executing an interrupt condition change instruction
03/18/2003US6534660 CC-1065 analog synthesis
03/18/2003US6534655 Indeno[1,2-C]pyrazole derivatives for inhibiting tyrosine kinase activity
03/18/2003US6534652 Intermediates for the preparation of substituted 1,2,3,4-tetrahydronaphthalene derivatives
03/18/2003US6534642 Isolated nucleic acid of given sequence encoding a protein; dysfunction of the human protein implicated in hyper/hypocalcemia, bone disorders, leukemia and cancer
03/18/2003US6534639 Guanidinium functionalized oligonucleotides and method/synthesis
03/18/2003US6534635 Tissue inhibitors of metalloproteinase (TIMP); electron-accepting group causes it to lose its ability to bind to metalloproteinase; carbamylation; inhibition of metastasis of cancer or vascularization
03/18/2003US6534633 Polyspecific binding molecules and uses thereof
03/18/2003US6534630 Connective tissue growth factor-2
03/18/2003US6534544 Methods of treatment with compounds having RARα receptor specific or selective activity
03/18/2003US6534506 Inhibitors of prenyl-protein transferase
03/18/2003US6534497 Substitute 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
03/18/2003US6534495 Anticoagulants that prevent thrombin-related diseases.
03/18/2003US6534488 32P or 33P-labelled bisphosphonates as radiotherapeutic radiopharmaceuticals. The 32P- or 33P-labelled bisphosphonates, which are chemically identical to the unlabelled agent, are expected to target the lesion site in
03/18/2003US6534483 Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods
03/18/2003US6534478 Cyclic azapeptides with angiogenic effect
03/18/2003US6534275 Isolated polypeptide having specified amino acid sequence or immunogenic fragment thereof
03/18/2003US6534261 Regulation of endogenous gene expression in cells using zinc finger proteins
03/18/2003US6534098 Paget's disease; osteoporosis
03/18/2003US6534061 Isolated DNA98853 and DNA101848 polypeptides
03/18/2003US6534056 Therapeutic and diagnostic uses of protein tyrosine phosphatase TC-PTP
03/18/2003US6534054 Probiotic/therapeutic uses of nonpathogenic probiobiotic microorganisms; manufacturing the formulation from the plant derived material
03/18/2003US6534053 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
03/18/2003US6534050 2-methyl-3-butenyl-1-pyrophosphoric acid salts and agents for treating lymphocytes
03/18/2003US6534041 Acid-labile and enzymatically divisible dye compounds for diagnosis with near infrared light and for therapy
03/18/2003CA2422500A1 Triazolo-epothilones
03/18/2003CA2298093C An anti-cancer therapy agent of arsenic hexoxide (as4o6) of a natural chemical substance and its pharmaceutical composition
03/18/2003CA2272705C Fused bicyclic pyrimidine derivatives
03/18/2003CA2269994C 7-hetero-bicyclo¬2.2.1|-heptanes
03/18/2003CA2244501C Arylsulfonylamino hydroxamic acid derivatives
03/18/2003CA2217351C Carbonyl-piperazinyl and piperidinyl compounds which inhibit farnesyl protein transferase
03/18/2003CA2071983C Beta-phenylisoserine derivative, preparation and use thereof
03/18/2003CA1341425C Antibodies to angiogenin: immunotherapeutic agents
03/17/2003WO2002022833A1 Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug
03/17/2003CA2422759A1 Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug
03/17/2003CA2403058A1 Dna encoding the chimpanzee prostaglandin e2 receptor ep4 subtype
03/14/2003WO2003025166A1 Therapeutic vaccination method, mutated peptides of hiv reverse transcriptase and their use for vaccination and diagnostic purposes
03/14/2003CA2460377A1 Therapeutic vaccination method, mutated peptides of hiv reverse transcriptase and their use for vaccination and diagnostic purposes
03/13/2003WO2003021273A2 Diagnosis of carcinomas
03/13/2003WO2003021263A1 Use of g protein-coupled receptor protein
03/13/2003WO2003021262A1 Screening method
03/13/2003WO2003020954A2 205p1b5 in treatment and detection of cancer
03/13/2003WO2003020949A2 Targeted nucleic acid constructs and uses related thereto
03/13/2003WO2003020947A2 Mid 9002, a human sulfatase family member and uses therefor
03/13/2003WO2003020930A1 IDENTIFICATION AND USE OF MAMMALIAN p21 INHIBITORS
03/13/2003WO2003020909A2 Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
03/13/2003WO2003020892A2 Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
03/13/2003WO2003020889A2 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
03/13/2003WO2003020763A2 Soluble t cell receptor
03/13/2003WO2003020762A1 Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions
03/13/2003WO2003020754A2 Inhibition of replication factor c
03/13/2003WO2003020753A1 Peptidic compounds selectively binding to p-selectin
03/13/2003WO2003020751A2 Homing peptides
03/13/2003WO2003020750A2 Antigen mimotopes and vaccine against cancers
03/13/2003WO2003020749A2 Ncam binding compounds
03/13/2003WO2003020748A1 Anti-cancer cyclopenta[g]quinazoline compounds
03/13/2003WO2003020739A2 Novel lna compositions and uses thereof
03/13/2003WO2003020724A1 Polycyclic guanine phosphodiesterase v inhibitors
03/13/2003WO2003020722A1 Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
03/13/2003WO2003020721A1 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
03/13/2003WO2003020711A1 Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin
03/13/2003WO2003020702A2 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
03/13/2003WO2003020699A2 Tyrosine kinase inhibitors
03/13/2003WO2003020690A1 Aryl sulfamate derivatives
03/13/2003WO2003020371A2 Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer
03/13/2003WO2003020325A2 Methods for sterilizing preparations containing albumin
03/13/2003WO2003020320A2 Nanoparticles comprising biologically active tnf which is immobilised on the same
03/13/2003WO2003020309A2 Compound
03/13/2003WO2003020306A1 Desensitizers
03/13/2003WO2003020300A1 Use of cyclopenta[g]quinazoline derivatives for treating cancer
03/13/2003WO2003020292A1 A product for prolonging life only made from biological materials
03/13/2003WO2003020291A1 Increased solubility flavanolignan preparations
03/13/2003WO2003020280A2 Compositions and use thereof in the treatment of cancer
03/13/2003WO2003020279A2 Compositions and methods of treatment of cancer
03/13/2003WO2003020278A1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
03/13/2003WO2003020272A1 Compositions and methods for the treatment of cancer
03/13/2003WO2003020266A1 Antineoplastic combinations
03/13/2003WO2003020264A1 Remedial agent for cancer and cancer preventive
03/13/2003WO2003020262A2 Use of polyunsaturated fatty acids for intra-arterial injection for selectively occluding blood supplies to neoplasias
03/13/2003WO2003020259A2 Combinations of dmxaa and other anti-cancer agents
03/13/2003WO2003020254A1 Pharmaceutical composition comprising (-)-secoisolariciresinol
1 ... 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 ... 2211